Search results for "Dali"

showing 10 items of 1372 documents

Magnetic Nanoparticle-Based Hyperthermia Mediates Drug Delivery and Impairs the Tumorigenic Capacity of Quiescent Colorectal Cancer Stem Cells

2021

Cancer stem cells (CSCs) are the tumor cell subpopulation responsible for resistance to chemotherapy, tumor recurrence, and metastasis. An efficient therapy must act on low proliferating quiescent-CSCs (q-CSCs). We here investigate the effect of magnetic hyperthermia (MHT) in combination with local chemotherapy as a dual therapy to inhibit patient-derived colorectal qCR-CSCs. We apply iron oxide nanocubes as MHT heat mediators, coated with a thermoresponsive polymer (TR-Cubes) and loaded with DOXO (TR-DOXO) as a chemotherapeutic agent. The thermoresponsive polymer releases DOXO only at a temperature above 44 °C. In colony-forming assays, the cells exposed to TR-Cubes with MHT reveal that qC…

0301 basic medicineHyperthermiacancer stem cellsmagnetic nanoparticlesMaterials scienceSettore MED/50 - Scienze Tecniche Mediche Applicatecolorectal cancerdoxorubicinMetastasis03 medical and health sciences0302 clinical medicineDrug Delivery SystemsIn vivoCancer stem cellmedicineHumansGeneral Materials ScienceDoxorubicinmagnetic hyperthermiaMagnetite NanoparticlesAntibiotics AntineoplasticHyperthermia Inducedmedicine.diseaseCombined Modality Therapy3. Good healthOxaliplatin030104 developmental biology030220 oncology & carcinogenesisDrug deliveryCancer researchNeoplastic Stem CellsStem cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioColorectal Neoplasmsmedicine.drugResearch Article
researchProduct

Danger signals: Chemotherapy enhancers?

2017

IF 9.614; International audience; Endogenous danger signals are molecules normally present in a given cell compartment that are rapidly released following cell stress and induce immune responses. We and others have shown that dying tumor cells treated with some chemotherapies are able to induce anticancer immune responses, which rely on their release of danger signals such as the nuclear protein HMGB1. DNA can also be released from chemotherapy-treated tumor cells, act as a danger signal, and boost anticancer immunity. While the immunostimulatory properties of DNA have been identified for decades, the recent discovery of a novel family of receptors, cytosolic DNA sensors, has provided a nov…

0301 basic medicineImmunologyCelleducationBiologyHMGB1CD8+ T cellschemotherapyCancer Vaccines03 medical and health sciences0302 clinical medicineImmune systemDrug TherapyNeoplasmsmedicineImmunology and AllergyCytotoxic T cellAnimalsHumanscancer[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMolecular Targeted TherapyNuclear proteinHMGB1 ProteinReceptorinnate immunityInnate immune systemDNAadaptive immunityAcquired immune systemCombined Modality TherapyImmunity Innate3. Good health030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinCancer research[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunotherapy030215 immunologySignal TransductionSTINGImmunological Reviews
researchProduct

Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.

2016

Abstract Background Adalimumab is effective in the treatment of Crohn's disease. We have already reported data on the efficacy of adalimumab in 110 steroid-dependent patients. At the end of the study 90 patients (64.5%) maintained clinical remission. Aims To assess efficacy and safety of adalimumab after 6 years in patients of the original cohort who responded to treatment. Methods The present study is an extension of the published paper on 90/110 patients. We report results on clinical remission and safety of 6 year maintenance therapy with adalimumab. Results Of the original cohort 90 patients completed the study, 17 were lost to follow-up and 3 died. At the end of follow-up (74.16 ± 10.3…

0301 basic medicineMaleAnti-Inflammatory AgentsKaplan-Meier EstimateSingle CenterInflammatory bowel diseaseInflammatory bowel disease0302 clinical medicineMaintenance therapyCrohn DiseaseLong term therapyProspective Studiesskin and connective tissue diseasesProspective cohort studyMultivariate AnalysiCrohn's diseaseRemission InductionGastroenterologyMiddle AgedCrohn's diseaseAnti-Inflammatory AgentTreatment OutcomeItalyCohort030211 gastroenterology & hepatologyFemaleSteroidsHumanmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtySteroid dependencyMaintenance Chemotherapy03 medical and health sciencesInternal medicinemedicineAdalimumabHumansAdverse effectSteroidHepatologybusiness.industryAdalimumabmedicine.diseaseSurgeryProspective Studie030104 developmental biologyMultivariate AnalysisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.

2020

Abstract Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was…

0301 basic medicineMaleNeoplasm Residualmedicine.medical_treatmentImmunoglobulin Variable RegionHematopoietic stem cell transplantationKaplan-Meier EstimateLymphoma Mantle-CellBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicinePiperidinesObinutuzumabAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overSulfonamidesHematopoietic Stem Cell TransplantationHematologyMiddle AgedCombined Modality TherapyProgression-Free Survival3. Good healthTreatment Outcome030220 oncology & carcinogenesisIbrutinibFemaleImmunoglobulin Heavy Chainsmedicine.medical_specialtyMaximum Tolerated DoseImmunologyAntibodies Monoclonal Humanized03 medical and health sciencesInternal medicinemedicineHumansProgression-free survivalAgedVenetoclaxbusiness.industryAdenineCell Biologymedicine.diseaseBridged Bicyclo Compounds HeterocyclicGenes p53Minimal residual diseaseHematologic Diseases030104 developmental biologychemistryMutationMantle cell lymphomabusinessFollow-Up StudiesBlood
researchProduct

Effects of transcranial random noise stimulation combined with Graded Repetitive Arm Supplementary Program (GRASP) on motor rehabilitation of the upp…

2019

We evaluated the combined use of transcranial random noise stimulation (tRNS) with the Graded Repetitive Arm Supplementary Program (GRASP) in sub-acute ischemic stroke patients suffering from arm impairment. Eighteen ischemic stroke patients with upper limb disability were randomly assigned to either the GRASP + tRNS or GRASP + Sham stimulation group. Fugl-Meyer Assessment-Upper extremity (FMA-UE) was performed to evaluate upper limb impairment before treatment (T0), after the last stimulation (T1) and after 30 days (T2). At T1 and T2, beneficial effects in the tRNS group correlated with better FMA-UE score than sham stimulation group (p < 0.001) and these results did not correlate to st…

0301 basic medicineMaleStroke rehabilitationmedicine.medical_specialtyNeurologyStimulationPilot ProjectsSub acuteTranscranial Direct Current StimulationUpper Extremity03 medical and health sciencesTranscranial random noise stimulation0302 clinical medicinePhysical medicine and rehabilitationDouble-Blind MethodmedicineHumansGraded Repetitive Arm Supplementary Program (Grasp)Biological PsychiatryPhysical Therapy ModalitiesAgedbusiness.industryGRASPTranscranial random noise stimulation combined (tRNS)BrainRecovery of FunctionCombined Modality TherapyMotor rehabilitationPsychiatry and Mental health030104 developmental biologymedicine.anatomical_structureTreatment OutcomeNeurologyIschemic strokeUpper limbFemaleSettore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.

2017

Objective Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. Methods Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin–etoposide–cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease. Results Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma (Dysg), 13 with immature teratoma and elevated serum alpha-fetoprotein levels (IT + AFP), and 38 with nondy…

0301 basic medicineMalechildhood; germ cell tumors; ovarianGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesStage (cooking)germ cell tumorsProspective cohort studyChildEtoposideOvarian NeoplasmsHematologychildhood germ cell tumors ovarianNeoplasms Germ Cell and EmbryonalPrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolFemalemedicine.medical_specialtyAdolescentOvariectomy03 medical and health sciencesBleomycinInternal medicineDysgerminomaovarianHumansSurvival ratechildhoodNeoplasm Stagingbusiness.industrySettore MED/20 - Chirurgia Pediatrica E InfantileInfantmedicine.diseaseSurgeryRegimen030104 developmental biologyPediatrics Perinatology and Child HealthSettore MED/20Immature teratomaGerm cell tumorsCisplatinbusinessProgressive diseaseFollow-Up StudiesPediatric bloodcancer
researchProduct

Functional Improvement after Photothrombotic Stroke in Rats Is Associated with Different Patterns of Dendritic Plasticity after G-CSF Treatment and G…

2016

We have previously shown that granulocyte-colony stimulating factor (G-CSF) treatment alone, or in combination with constraint movement therapy (CIMT) either sequentially or concomitantly, results in significantly improved sensorimotor recovery after photothrombotic stroke in rats in comparison to untreated control animals. CIMT alone did not result in any significant differences compared to the control group (Diederich et al., Stroke, 2012;43:185-192). Using a subset of rat brains from this former experiment the present study was designed to evaluate whether dendritic plasticity would parallel improved functional outcomes. Five treatment groups were analyzed (n = 6 each) (i) ischemic contr…

0301 basic medicineMalemedicine.medical_specialtyLightmedicine.medical_treatmentMovement10208 Institute of NeuropathologyIschemialcsh:Medicine610 Medicine & health1100 General Agricultural and Biological Sciences03 medical and health sciences0302 clinical medicine1300 General Biochemistry Genetics and Molecular BiologyInternal medicineNeuroplasticityGranulocyte Colony-Stimulating FactormedicineAnimalscardiovascular diseasesRats Wistarlcsh:ScienceSalineStrokePhysical Therapy Modalities1000 MultidisciplinaryMultidisciplinaryNeuronal Plasticitybusiness.industryPyramidal Cellslcsh:RDendritesRecovery of Functionmedicine.diseaseCombined Modality TherapyCortex (botany)SurgeryGranulocyte colony-stimulating factorConstraint-induced movement therapyStroke030104 developmental biologyEndocrinologyConcomitant570 Life sciences; biologylcsh:Qbusiness030217 neurology & neurosurgeryResearch ArticlePLoS ONE
researchProduct

Emergent Uric Acid Treatment is Synergistic with Mechanical Recanalization in Improving Stroke Outcomes in Male and Female Rats.

2018

Preclinical and clinical studies support a promising, albeit not definitive, neuroprotective effect of emergent uric acid (UA) administration in ischemic stroke. We assessed the effects of UA in an ischemic stroke model relevant to the current treatment paradigm of mechanical thrombectomy within the STAIR/RIGOR recommendations. A cohort of male and female Wistar rats was subjected to ischemic stroke with mechanical recanalization under physiological monitoring. The effects of transient middle cerebral artery occlusion (tMCAO) with adjunctive UA (IV, 16 mg/kg) or vehicle treatment were assessed at 24 h and 7 days. Outcomes included neurofunctional impairment, brain infarct (TTC staining, MRI…

0301 basic medicineMalemedicine.medical_specialtyMechanical ThrombolysisBrain damageNeuroprotectionBrain Ischemia03 medical and health sciencesCresyl violetchemistry.chemical_compoundRandom Allocation0302 clinical medicineuric acidInternal medicineEdemamedicineischemic strokeAnimalsRats WistarStrokebusiness.industryGeneral Neurosciencerat modeladjunctive treatmentBrainRecovery of Functionmedicine.diseaseCombined Modality TherapyUric AcidStrokeDisease Models Animal030104 developmental biologyNeuroprotective AgentschemistrythrombectomyAdjunctive treatmentIschemic strokeCardiologyUric acidneuroprotectionFemalemedicine.symptombusiness030217 neurology & neurosurgeryNeuroscience
researchProduct

The Effects of Static and Dynamic Visual Representations as Aids for Primary School Children in Tasks of Auditory Discrimination of Sound Patterns. A…

2018

It has been proposed that non-conventional presentations of visual information could be very useful as a scaffolding strategy in the learning of Western music notation. As a result, this study has attempted to determine if there is any effect of static and dynamic presentation modes of visual information in the recognition of sound patterns. An intervention-based quasi-experimental design was adopted with two groups of fifth-grade students in a Spanish city. Students did tasks involving discrimination, auditory recognition and symbolic association of the sound patterns with non-musical representations, either static images (S group), or dynamic images (D group). The results showed neither s…

0301 basic medicineMusical notationmedia_common.quotation_subjecteducationEducació primàriaNotationEducationstatic-dynamic presentation discrimination of melodic patterns03 medical and health sciencesPresentationCovariateDigital learningAssociation (psychology)media_commonlcsh:T58.5-58.64lcsh:Information technologyGeneral Engineeringcomputer.file_formatMusic education030104 developmental biologymusic educationImage file formatslcsh:LPsychologybimodalitycomputerlcsh:EducationCognitive psychologyInternational Journal of Emerging Technologies in Learning (iJET)
researchProduct

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct